Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth
Rhea-AI Summary
Intelligent Bio Solutions (Nasdaq: INBS) reported fiscal 2026 first quarter results for the period ended September 30, 2025, delivering record quarterly revenue of $1,111,797, up 32% sequentially and 28% year‑over‑year. Cartridge consumable sales totaled $640,300, representing 57.59% of revenue. Gross profit margin improved by 690 basis points to 46.6%, attributed to operational efficiency and a higher mix of cartridge sales. The company added 33 net new customer accounts (total active accounts: 492 across 24+ countries), secured a multi‑site contract in London covering 4,400 staff, launched the SmarTest Patch, and signed a global distribution agreement with SMARTOX for markets outside the U.S. and Canada.
Management highlighted consumable‑led recurring revenue momentum and margin expansion while advancing toward planned FDA clearance and U.S. market entry.
Positive
- Record quarterly revenue of $1.11M
- Revenue growth +28% YoY
- Sequential revenue increase of +32%
- Gross margin improved +690 bps to 46.6%
- Cartridge sales = 57.59% of revenue
- Added 33 new customer accounts (total 492)
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, INBS declined 1.72%, reflecting a mild negative market reaction. Argus tracked a peak move of +20.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $128K from the company's valuation, bringing the market cap to $7M at that time.
Data tracked by StockTitan Argus on the day of publication.
Record quarterly revenue of
Gross profit margins increased 690 basis points year-over-year to
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025.
The fiscal 2026 first quarter delivered record quarterly revenue of
"Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "We achieved record quarterly revenue of
Key Financial and Operational Highlights
- Revenue of
$1,111,797 , up32% sequentially from the fiscal fourth quarter 2025 and28% year-over-year from the fiscal first quarter 2025. - Cartridge sales of
$640,300 represented57.59% of total revenue, up from51.1% in the fiscal first quarter of 2025, demonstrating the strength of the Company's recurring revenue model. - Gross profit margins increased to
46.6% from39.68% in the fiscal first quarter of 2025, reflecting improved operational efficiency and product mix optimization. - Added 33 new customer accounts during the quarter, bringing the Company's total number of active accounts to 492 across 24+ countries.
Strategic Market Expansion and Partnerships
- Secured a major contract with a London public transport operator covering 14 operational sites and over 4,400 staff, representing a significant scale deployment.
- Expanded product portfolio with the addition of the SmarTest® Patch, an innovative 7-10 day continuous drug monitoring solution.
- Established a global distribution agreement with SMARTOX® to bring its SmarTest Patch technology to international markets outside of the U.S. and Canada.
"As our first fiscal quarter results show, the financial discipline implemented throughout fiscal 2025 is now translating into meaningful margin expansion and operational leverage," said Spiro Sakiris, CFO at Intelligent Bio Solutions. "We are seeing strong returns on strategic investments, with improved customer acquisition metrics and accelerating revenue per account. We believe that we are well positioned to capitalize on the growth opportunities ahead."
INBS's proprietary fingerprint technology addresses key pain points in drug screening, including privacy and dignity, user experience, and operational efficiency, positioning the Company to capitalize on the growing demand for non-invasive, rapid drug screening solutions. The addition of the SmarTest® Patch and SMARTOX® partnership, combined with INBS's international expansion and proven ability to secure large-scale deployments, positions the Company for continued revenue diversification and market growth throughout fiscal 2026.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
| Intelligent Bio Solutions Inc. Condensed Consolidated Balance Sheets | ||||||||
| As of September 30, | As of June 30, | |||||||
| 2025 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 1,660,105 | $ | 1,019,909 | ||||
| Accounts receivable, net | 717,823 | 594,614 | ||||||
| Inventories | 628,177 | 635,215 | ||||||
| Research and development tax incentive receivable | 924,062 | 734,408 | ||||||
| Assets held for sale | 66,020 | 327,500 | ||||||
| Other current assets | 488,182 | 826,976 | ||||||
| Total current assets | 4,484,369 | 4,138,622 | ||||||
| Property and equipment, net | 271,745 | 251,325 | ||||||
| Operating lease right-of-use assets | 1,808,892 | 69,520 | ||||||
| Intangibles, net | 3,473,303 | 3,790,319 | ||||||
| Total assets | $ | 10,038,309 | $ | 8,249,786 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 3,992,427 | $ | 4,534,246 | ||||
| Current portion of operating lease liabilities | 362,801 | 84,659 | ||||||
| Current employee benefit liabilities | 567,059 | 534,990 | ||||||
| Notes payable | 139,787 | 197,146 | ||||||
| Total current liabilities | 5,062,074 | 5,351,041 | ||||||
| Employee benefit liabilities, less current portion | 100,041 | 84,921 | ||||||
| Operating lease liabilities, less current portion | 1,449,265 | - | ||||||
| Total liabilities | 6,611,380 | 5,435,962 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity | ||||||||
| Common stock, | 90,985 | 73,230 | ||||||
| Treasury stock, at cost, 116 shares as of September 30, 2025 and June 30, 2025 | (1 | ) | (1 | ) | ||||
| Additional paid-in capital | 69,325,542 | 65,783,916 | ||||||
| Accumulated deficit | (65,516,071 | ) | (62,533,065 | ) | ||||
| Accumulated other comprehensive loss | (279,228 | ) | (327,944 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 3,621,227 | 2,996,136 | ||||||
| Non-controlling interest | (194,298 | ) | (182,312 | ) | ||||
| Total shareholders’ equity | 3,426,929 | 2,813,824 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 10,038,309 | $ | 8,249,786 | ||||
| Intelligent Bio Solutions Inc. Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) | ||||||||
| Three Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 1,111,797 | $ | 872,287 | ||||
| Cost of revenue (exclusive of amortization shown separately below) | (593,506 | ) | (525,486 | ) | ||||
| Gross profit | 518,291 | 346,801 | ||||||
| Other income | ||||||||
| Government support income | 193,267 | 126,128 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative expenses | (2,659,824 | ) | (1,949,016 | ) | ||||
| Development and regulatory approval expenses | (486,169 | ) | (948,752 | ) | ||||
| Depreciation and amortization | (303,378 | ) | (300,422 | ) | ||||
| Impairment of long-lived assets | (261,780 | ) | - | |||||
| Total operating expenses | (3,711,151 | ) | (3,198,190 | ) | ||||
| Loss from operations | (2,999,593 | ) | (2,725,261 | ) | ||||
| Other income (expense), net | ||||||||
| Interest expense | (3,903 | ) | (22,327 | ) | ||||
| Realized foreign exchange loss | - | (51 | ) | |||||
| Interest income | 8,504 | 52,840 | ||||||
| Total other income, net | 4,601 | 30,462 | ||||||
| Net loss | (2,994,992 | ) | (2,694,799 | ) | ||||
| Net loss attributable to non-controlling interest | (11,986 | ) | (9,166 | ) | ||||
| Net loss attributable to Intelligent Bio Solutions Inc. | $ | (2,983,006 | ) | $ | (2,685,633 | ) | ||
| Other comprehensive income (loss) | ||||||||
| Foreign currency translation gain | 48,716 | 216,355 | ||||||
| Total other comprehensive income | 48,716 | 216,355 | ||||||
| Comprehensive loss | (2,946,276 | ) | (2,478,444 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (11,986 | ) | (9,166 | ) | ||||
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | $ | (2,934,290 | ) | $ | (2,469,278 | ) | ||
| Net loss per share, basic and diluted | $ | (0.35 | ) | $ | (0.70 | ) | ||
| Weighted average shares outstanding, basic and diluted | 8,546,934 | 3,811,090 | ||||||
FAQ
What were Intelligent Bio Solutions (INBS) fiscal Q1 2026 revenues on Nov 12, 2025?
How much did INBS cartridge sales contribute to Q1 2026 revenue?
How did Intelligent Bio Solutions' gross margin change in fiscal Q1 2026?
What customer growth did INBS report for fiscal Q1 2026?
What commercial deals did INBS announce in Q1 2026 that affect revenue diversification?
What operational milestones did INBS disclose on Nov 12, 2025 regarding product expansion?
